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The replication of human immunodeficiency virus type 1 in mononuclear phagocytes (blood monocytes, tissue macro- 
phages, and dendritic ells} is an important feature of HIV-1 pathogenesis. Although most primary HIV-1 isolates are able 
to productively infect monocytes, some reports suggest hat rates of viral DNA synthesis and virus replication are reduced 
in HIV-l-infected monocytes as compared to infected T cells. In this study we compare kinetics of viral DNA synthesis in 
CD4 + T cells and monocytes following HIV-1 infection. Our results indicate that reverse transcription of viral nucleic acids 
following infection of monocytes occurs at rates equal to or greater than that observed following infection of T cells. These 
studies reveal no postentry restrictions to HIV-1 replication following infection in monocytes. Moreover, the results support 
the notion that both monocytes and CD4 + T cells are equally permissive for virus replication in infected individuals. © 1995 
Academic Press, Inc. 
The tropism of HIV-1 for cells of macrophage lineage 
is an important feature of lentivirus pathogenesis (1, 2). 
HIV-1 infection of tissue macrophages may play a central 
role in virus establishment as macrophages are one of 
the first cells infected by HIV-1 in the human host (2, 3). 
In contrast to the rapid cytopathic manifestations of HIV- 
1 replication in T cells (4, 5) macrophages appear less 
susceptible to virus-induced cytopathicity (2). Thus, mac- 
rophages may serve as a stable reservoir for the dissemi- 
nation and persistence of HIV-1 in brain, lymph nodes, 
and lung throughout subclinical infection and disease 
(6-8). The characteristics of macrophage infections are 
not well defined. Exposure of macrophages to any of the 
multitude of exogenous and endogenous differentiation 
stimuli regulates viral replication (9-11) and the control 
of HIV-1 persistence. A variety of reports demonstrate 
that cellular control mechanisms influence permis- 
siveness ( 12-  14) of macrophages to productive lentiviral 
infection and underscore differences between macro- 
phage and T cell infections. For example, low levels of 
IFN-/~ and T and/or other negative regulatory factors may 
be induced after exposure of monocytes to HIV-1 (9, 15). 
These factors may regulate early stages of virus replica- 
tion in monocytes and may underlie the differences in 
susceptibility of monocytes to HIV-1 infection. 
Several studies suggest that macrophages are less 
permissive than T cells to productive HIV-1 infection (5, 
11, 16). Since macrophages are terminally differentiated 
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nondividing host cells for HIV-1, viral nucleic acids must 
traverse the nuclear membrane before provirus estab- 
lishment and viral replication can occur. Since the first 
clear report demonstrating that nondividing macro- 
phages permitted provirus establishment (17), it has 
been shown that nucleophilic components associated 
with the preintegration complex of HIV-1 facilitate nuclear 
localization of viral nucleic acids in the absence of mito- 
sis (18-20) .  Taken together, these reports would indicate 
that the restriction to virus replication in macrophages 
is not at the level of host cell mitosis. Several studies 
have demonstrated that reverse transcription of viral nu- 
cleic acids is inefficient when nucleotide precursor levels 
in the cell are limited as in quiescent (Go) T-lymphocytes. 
This has prompted the suggestion that limited levels of 
• nucleotide precursors in macrophages may influence vi- 
ral DNA synthesis and limit the kinetics of spreading 
infection. In support of this hypothesis, recent studies 
have demonstrated inefficient synthesis of viral DNA fol- 
lowing infection of monocyte-derived macrophages (34, 
11, 21). Although reverse transcription rates in infected 
macrophages could be increased by the addition of exog- 
enous nucleotide precursors, they did net reach rates 
seen in activated T cells. This suggested that the kinetics 
of HIV-1 replication in blood macrophages is influenced 
by limitations in the cellular nucleotide pool (11, 21). 
The replication parameters of monocyte tropic (HIV- 
1ADA; HIV-1DJV) HIV-1 in monocyte-derived macrophages 
and lymphoblasts are shown in Fig. 1. Both viruses elic- 
ited a spreading infection in macrophages with kinetics 
similar to that observed in lymphoblasts (Fig. 1). The 
replication rate of monocyte tropic HIV-1 variants in 
lymphoblasts was similar to that for the IIIB-derived T 
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FiG. 1. Replication of monocyte tropic HIV-1 variants in primary mono- 
cyte-derived macrophages (circles) and phytohemagglutinin (PHA)-acti- 
vated peripheral blood lymphocytes ( quares). Lymphocytes and mono- 
cytes were isolated by counter-current centrifugal elutriation of mono- 
nuclear leukocyte-rich cell preparations obtained from normal HIV-1 
and hepatitis B seronegative donors by leukapheresis. Lymphocytes 
were activated by PHA (2 #g/ml) overnight and then cultured in the 
presence of interleukin 2 (IL-2). Elutriated monocytes were cultured in 
24-well microtiter plates as adherent monolayers in medium containing 
MCSF (1000 U/ml, a generous gift from Genetic Institute, Cambridge, 
MA) for 7 to 10 days prior to HIV-1 infection (10). Cells were infected 
with the indicated HIV-1 isolate at two multiplicities of infection (0.1 
(top) and 0.01 per cell (bottom), which is equivalent to 1 X 105 and 1 
X 104 cpm per 7.5 x 105 cells). HIVAD A has been described previously 
(42); HIV-IDN is a clinical monocyte tropic isolate which was obtained 
at autopsy from the brain of an individual who had died of AIDS. Two 
hours after infection, culture supernatants containing virions were re- 
moved and replaced with fresh culture medium. At 2- to 3-day intervals, 
culture supernatants were harvested in triplicate for measurement of
reverse transcriptase activity. 
cell line-adapted HIV-1MF virus variant (not shown). Thus, 
under the experimental conditions utilized here, there did 
not appear to be any restriction in the ability of HIV-1 to 
establish a spreading infection in macrophages when 
compared to lymphoblasts. 
We next compared the kinetics of reverse transcription 
of viral nucleic acids following infection of lymphoblasts 
and monocytes. Synthesis of early, intermediate, and late 
products of reverse transcription were identified by poly- 
merase chain reaction (PCR) and primers to LTR U3/R, 
pol, and LTF{ R/gag regions of the viral genome, respec- 
tively (22, 23). The examination of de novo DNA synthesis 
following acute HIV infection is limited by the presence of 
preexisting viral DNA (proviral (23) and virion-associated 
DNA (24, 25)) in the inoculum. Treatment of the inoculum 
with DNase (23) does not completely eliminate input pro- 
viral DNA forms and, in particular, has little effect on 
virus-associated DNA (M. Stevenson, unpublished ob- 
servations). Therefore, the contribution of virion-associ- 
ated DNA was excluded by comparing yiral DNA synthe- 
sis in drug free with that in AZT containing lymphoblast 
cultures. To provide more definitive vidence for the pres- 
ence of full-length plus and minus strand viral DNA we 
compared the synthesis of 1 and 2 LTR circle forms of 
episomal viral IbNA in infected cells. Although these epi- 
somal forms of viral DNA do not appear to represent 
provirus precursors (26-28), they are formed only after 
synthesis of full-length viral DNA and its transport to the 
host cell nucleus (22, 26). In addition, such episomal 
forms are not found within the virus inoculum but are 
formed only within acutely infected cells (M. Stevenson, 
unpublished observations). The accumulation of early, 
intermediate, and late products of reverse transcription 
including nuclear episomal forms of viral DNA in HIV-1- 
infected lymphoblasts is illustrated in Fig. 2. De novo 
synthesis of early, intermediate, and late reverse tran- 
scription intermediates (when compared to levels ob- 
served in AZT-treated cultures) was evident by 8 hr after 
infection with the HIV-1ADA isolate. In particular, when 
compared with AZT-treated cultures, there was a clear 
increase in the PCR signal generated by LTR U3/R and 
poll/J primers at 8 hr postinfection and at 24 hr postinfec- 
tion using LTR U3/gag (late) primers (Fig. 2). Similar rates 
of accumulation of reverse transcription intermediates 
were observed following infection of lymphoblasts by 
HIV-IDjv (compare LTR U3/gag products at 8 and 24 hr 
postinfection with AZT controls). Episomal HIV-I DNA 
forms containing 1 LTR (1 LTR circle) were evident by 24 
and 36 hr postinfection with HIV-lAaA and HIV-luJv iso- 
lates, respectively. Episomal forms of viral DNA con- 
taining 2 LTRs (2 LTR circle) which are typically observed 
in lower abundance in retrovirus-infected cells (29) were 
detectible by 36 and 48 hr after infection with HIV-lAu A 
and HIV-IDN isolates, respectively. This suggests that 
under culture conditions and multiplicities of infection 
utilized here, viral DNA synthesis in HIV-1ADA- and HIV- 
1ujv-infected lymphoblasts was complete by at least 24 
and 36 hr postinfection, respectively. 
We next examined the accumulation of viral reverse 
transcription products following infection of monocyte- 
derived macrophages (Fig. 3). Although some virion-as- 
sociated strong stop DNA (identified using LTR U3/R 
primers) was evident in AZT-treated cultures, there ap- 
peared to be very little, if any, association of proviral DNA 
forms in the inoculum (23) (identified using poll/J and 
LTR U3/gag primers) with monocytes. The reason for the 
differences in uptake of preexisting proviral DNA forms 
by lymphocytes and monocytes is unclear but may relate 
to the different biophysical properties of these cells. 
Early, intermediate, and late products of reverse tran- 
scription were evident by 8 hr postinfection with the HIV- 
lAD A isolate, while accumulation of late products of re- 
verse transcription was somewhat delayed in HIV-1uJv- 
infected cultures (Fig. 3). One LTR circle forms of viral 
DNA were evident as early as 8 hr postinfection with 
HIV-IADA although their appearance was greatly delayed 
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RG. 2. Synthesis of viral DNA in lymphoblasts following HIV-1 infection. At the indicated times postinfection, lymphoblasts (5 x 10 ~ cells) were 
taken for isolation of total cellular DNA and analysis by PCR (19). In AZT-treated cultures, drug (1 #M) was added to lymphoblast and monocyte 
cultures for 18 hr prior to infection and was maintained in cultures throughout he period of the experiment. DNA from 5 x 104 cells was subjected 
to 30 cycles of PCR with primers to LTR U3 and R (coordinates 9194-9214 and 9591-9610 of HIV HXB2; (43) poll and J (coordinates 2131-2149 
and 2592-2610); LTR U3 and gag (coordinates 9194-9214 and 794-815) for amplification of early, intermediate and late reverse transcription 
products, respectively. Amplification of episomal forms of viral DNA containing 1 and 2 LTRs was performed using ag and nef (coordinates 912- 
931 and 9008-9028) and LTR R and U5 (coordinates 9591-9610 and 9650-9679) primers, respectively. For LTR primers, only 3 r LTR coordinates 
are given. PCR amplification products were visualized after Southern blot transfer and hybridization with 32P-labeled oligonucleotide probes. 
Hybridized blots were visualized on a molecular phosphorimager SF (Molecular Dynamics). Standards for LTR U3/R, poll/J, and LTR R/gag products 
were generated by PCR on doubling dilutions of DNA from 8E5 cells which contain one defective viral genome per cell (44). Standards for 1 and 
2 LTR circle forms of viral DNA were generated from doubling dilutions of HIV-l-infected CD4 + MT-4 cells. 
in monocytes infected with HIV-1DN. We do not attach 
much s igni f icance to d i f ferences in 1 LTR c i rc le accumu-  
lation between the two  HIV-1 var iants  s ince accumulat ion  
of 2 LTR circle forms of viral DNA occur red  at re lat ively 
s imi lar  late rates in HIV-1ADA- and HIV- lp jv - in fected 
monocytes  (Fig. 3). Taken  together ,  the data ind icates  
that viral DNA synthes is  p roceeds  rapid ly  to complet ion  
in monocytes  and at rates equal  to or greater  than that 
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FiG. 3. Synthesis of viral DNA in HIV-l-infected monocytes. Monocytes were established in 24-well plates. Cells were harvested by scraping and 
DNA was isolated as described elsewhere (19). Early, intermediate, and late products of reverse transcription and episomal forms of viral DNA 
were amplified using primer pairs identified in Fig. 2. 
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FIG. 4. Synthesis of viral DNA in lymphoblasts and monocyte-derived macrophages after infection with a T cell line-adapted HIV-1 variant. 
Lymphoblasts and monocytes were infected in parallel with HIV'IMF (30) as outlined in Fig. 1. At the indicated times postinfection, cells were 
harvested for isolation and amplification of viral DNA from 5 x 104 ceils as described in the legend to Fig. 2. 
observed in lymphoblasts. The comparable rates of re- 
verse transcription in both cell systems are supported 
by comparable rates with which monocyte tropic HIV-1 
variants elicited a spreading infection in lymphoblasts 
and monocytes as shown in Fig. 1. 
To address whether contaminating lymphoblasts in the 
macrophage cultures contributed to the observed pat- 
terns of virus replication and DNA synthesis, we exam- 
ined viral DNA synthesis in monocytes infected with a T 
cell line-adapted HIV-1 variant, HIV-I•F (30). T cell line- 
adapted HlWl isolates are unable to replicate in primary 
monocytes, a restriction which is manifest at the level 
of virus entry (fusion, uncoating) and which precludes 
synthesis of viral cDNA (31). In monocytes infected with 
HIV-1MF there was no evidence of any de novo viral 
DNA synthesis despite efficient reverse transcription in 
lymphoblasts infected with this virus (Fig. 4). Since mac- 
rophage cultures were refractory to infection by the T 
cell line-adapted HIV-IMF isolate, it is unlikely that the 
presence of contaminating lymphocytes in the mono- 
cytes could account for the efficient viral DNA synthesis 
and virus replication observed after infection with mono- 
cyte tropic HIV-1 isolates. 
The results described in this report indicate that under 
the culture conditions used in this study, monocytes are 
as permissive to HIV-1 infection and replication as 
lymphoblasts and demonstrate that conditions for re- 
verse transcription of viral nucleic acids are not rate lim- 
iting. These studies also support previous observations 
indicating that the restriction to macrophage infection by 
T cell line-adapted HIV-1 isolates is manifest at the level 
of virus entry, prior to the initiation of reverse transcrip- 
tion (31) rather than at a step which follows synthesis of 
viral DNA (32-34). The differences in results between 
this and previous studies (11, 21) likely reflects the viral 
isolate or the conditions for isolation and maintenance 
of monocytes. HIV-1ADA and HIV-1DJV are highly adapted 
monocyte tropic strains which replicate to high titers and 
are cytopathic for macrophages. Thus, the rates of viral 
DNA synthesis and virus replication observed in this 
study may be a reflection of the highly permissive infec- 
tion that ensues following infection of monocytes by 
these variants. However, differences in rates of viral DNA 
synthesis are more likely to be governed by differences 
in the host cell environment han the virus isolate. In this 
regard, recombinant human macrophage colony stimu- 
lating factor (MCSF) is used in our studies for initiation of 
monocyte cultures. MCSF enhances long-term monocyte 
survival in the absence of cell proliferation (35, 36) and 
HIV-1 replication is greatly enhanced in monocytes con- 
taining MCSF (10). Although MOSF is used only during 
initiation of cultures and not during the period of spread- 
ing virus infection this may be sufficient to prime macro- 
phages and facilitate their permissiveness to virus repli- 
cation. Moreover, during the course of in vitro propaga- 
tion, monocyte-derived macrophages can synthesize 
their own MCSF. Human sera used to cultivate mono- 
cytes contain up to 500 U/ml of MCSF (37, 38). Thus, 
although the addition of MCSF at the initiation of mono- 
cyte culture is likely a biologically relevant system, this 
alone cannot explain differences in permissiveness of 
cells to productive HIV-1 infection. A series of reports 
suggests that cytokines or other immune factors re- 
leased as a consequence of monocyte/macrophage acti- 
vation after HIV-1 infection regulate the initial events of 
viral replication in monocytes (9, 15). IFN-~, -/~, or-i/, 
TNFa, or IL-1/3 produced as a consequence of HIV-1 
replication could control initial events of virus/macro- 
phage interactions (39). Although addition of many of 
these factors can regulate virus replication in monocytes, 
like MCSF, the endogenous production of cytokines as 
a consequence of HIV-1 infection collectively are low and 
ultimately fail to control virus replication (12, 40). Indeed, 
a number of reports show no constitutive cytokine pro- 
duction following HIV-1 monocyte infection (12, 40, 41). 
Thus, at present, no clear explanations can be forwarded 
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for the differences in rates of virus replication in mono- 
oytes in this compared with previous studies. These is- 
Sues aside, our studies indicate that under certain condi- 
tions and with certain virus isolates, the macrophage is 
a highly permissive cell for productive HIV-1 infection. 
This underscores the importance of the tissue macro- 
phage as a reservoir for HIV-1 dissemination and persis- 
tence. 
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